Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -42.04% is 46% below its 5-year average of -28.85%, near the low end of its 5-year range (-48.59%–-6.45%).
42.12% below its 12-month average of -29.58%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.99%.
RETURN ON ASSETS (ROA)
-42.04%
RETURN ON ASSETS (ROA) AVG TTM
-29.58%
RETURN ON ASSETS (ROA) AVG 3Y
-35.66%
RETURN ON ASSETS (ROA) AVG 5Y
-28.85%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-42.12%
CURRENT VS 3Y AVG
-17.88%
CURRENT VS 5Y AVG
-45.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-30.40%
vs the sector median at left
Olema Pharmaceuticals, Inc.
Market Cap
$688.30M
Return on Assets (ROA)
-42.04%
TTM Avg
-29.58%
3Y Avg
-35.66%
5Y Avg
-28.85%
Market Cap
$689.85M
Return on Assets (ROA)
-36.26%
TTM Avg
-29.77%
3Y Avg
-47.75%
5Y Avg
-50.63%
Market Cap
$683.91M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
Market Cap
$688.73M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$684.40M
Return on Assets (ROA)
-98.15%
TTM Avg
-106.83%
3Y Avg
-87.42%
5Y Avg
-76.51%
Market Cap
$676.87M
Return on Assets (ROA)
-49.24%
TTM Avg
-70.53%
3Y Avg
-58.08%
5Y Avg
-52.49%
Market Cap
$704.20M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$676.27M
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
-52.36%
Market Cap
$709.36M
Return on Assets (ROA)
2.24%
TTM Avg
3.98%
3Y Avg
2.51%
5Y Avg
4.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $688.30M | -42.04% | -29.58% | -35.66% | -28.85% |
| Wave Life Sciences Ltd. (WVE)vs › | $689.85M | -36.26% | -29.77% | -47.75% | -50.63% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.91M | -103.29% | -79.28% | -61.36% | -60.54% |
| Anteris Technologies Global Corp. (AVR)vs › | $688.73M | -38.01% | -251.96% | -211.47% | -174.45% |
| Verastem, Inc. (VSTM)vs › | $684.40M | -98.15% | -106.83% | -87.42% | -76.51% |
| Solid Biosciences Inc. (SLDB)vs › | $676.87M | -49.24% | -70.53% | -58.08% | -52.49% |
| Cytek Biosciences, Inc. (CTKB)vs › | $704.20M | -18.03% | -7.81% | -4.40% | -1.35% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $676.27M | -41.48% | -39.59% | -35.47% | -52.36% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.36M | 2.24% | 3.98% | 2.51% | 4.09% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.21M | -20.44% | -45.26% | -91.41% | -102.66% |
ROA
-42.0%
ROE
-47.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.45% |
| 2024-12-31 | -28.71% |
| 2023-12-31 | -34.90% |
| 2022-12-31 | -48.59% |
| 2021-12-31 | -24.02% |
| 2020-12-31 | -6.45% |
| 2019-12-31 | -3269.70% |
| 2018-12-31 | -67.17% |
